# Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors

> **NCT01642342** · PHASE1 · TERMINATED · sponsor: **University of Southern California** · enrollment: 102 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **BIOLOGICAL:** recombinant albumin fusion protein sEphB4-HSA

## Key facts

- **NCT ID:** NCT01642342
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-09-06
- **Primary completion:** 2019-05-29
- **Final completion:** 2019-05-29
- **Target enrollment:** 102 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2022-08-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01642342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01642342, "Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01642342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*